Literature DB >> 19606124

For cancer, seek and destroy or live and let live?

Nicolas André, Eddy Pasquier.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19606124     DOI： 10.1038/460324c

Source DB:  PubMed          Journal:  Nature        ISSN： 0028-0836            Impact factor:   49.962


× No keyword cloud information.
  2 in total

1.  A change of strategy in the war on cancer.

Authors:  Robert A Gatenby
Journal:  Nature       Date:  2009-05-28       Impact factor: 49.962

2.  Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity.

Authors:  G Klement; S Baruchel; J Rak; S Man; K Clark; D J Hicklin; P Bohlen; R S Kerbel
Journal:  J Clin Invest       Date:  2000-04       Impact factor: 14.808
  2 in total
  6 in total

Review 1.  Metronomic chemotherapy: new rationale for new directions.

Authors:  Eddy Pasquier; Maria Kavallaris; Nicolas André
Journal:  Nat Rev Clin Oncol       Date:  2010-06-08       Impact factor: 66.675

Review 2.  Control dominating subclones for managing cancer progression and posttreatment recurrence by subclonal switchboard signal: implication for new therapies.

Authors:  Shengwen Calvin Li; Katherine L Lee; Jane Luo
Journal:  Stem Cells Dev       Date:  2011-11-02       Impact factor: 3.272

Review 3.  Metronomics: towards personalized chemotherapy?

Authors:  Nicolas André; Manon Carré; Eddy Pasquier
Journal:  Nat Rev Clin Oncol       Date:  2014-06-10       Impact factor: 66.675

4.  Evidence for new targets and synergistic effect of metronomic celecoxib/fluvastatin combination in pilocytic astrocytoma.

Authors:  Sandy Mercurio; Laetitia Padovani; Carole Colin; Manon Carré; Aurélie Tchoghandjian; Didier Scavarda; Sally Lambert; Nathalie Baeza-Kallee; Carla Fernandez; Céline Chappé; Nicolas André; Dominique Figarella-Branger
Journal:  Acta Neuropathol Commun       Date:  2013-05-20       Impact factor: 7.801

5.  Metronomic Four-Drug Regimen Has Anti-tumor Activity in Pediatric Low-Grade Glioma; The Results of a Phase II Clinical Trial.

Authors:  Arnauld Verschuur; Marie-Amélie Heng-Maillard; Philippe Dory-Lautrec; Romain Truillet; Elisabeth Jouve; Pascal Chastagner; Pierre Leblond; Isabelle Aerts; Stéphane Honoré; Natasha Entz-Werle; Nicolas Sirvent; Jean-Claude Gentet; Nadège Corradini; Nicolas André
Journal:  Front Pharmacol       Date:  2018-09-27       Impact factor: 5.810

Review 6.  Future paradigms for precision oncology.

Authors:  Giannoula Lakka Klement; Knarik Arkun; Dalibor Valik; Tina Roffidal; Ali Hashemi; Christos Klement; Paolo Carmassi; Edward Rietman; Ondrej Slaby; Pavel Mazanek; Peter Mudry; Gabor Kovacs; Csongor Kiss; Koen Norga; Dobrin Konstantinov; Nicolas André; Irene Slavc; Henk van Den Berg; Alexandra Kolenova; Leos Kren; Jiri Tuma; Jarmila Skotakova; Jaroslav Sterba
Journal:  Oncotarget       Date:  2016-07-19
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.